Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Tscan Therapeutics Inc's Business Segments
Tscan Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable Segment
Total Revenue
$ 1
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable Segment100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable Segment | $ 1 | 100% |
Description of Tscan Therapeutics Inc
Tscan Therapeutics Inc is a biotechnology company primarily focused on developing and commercializing T cell receptor (TCR) therapies for the treatment of cancer. TCR therapies harness the power of T cells, a type of immune cell, to specifically recognize and target cancer cells for destruction.
The company is headquartered in Cambridge, Massachusetts, USA, and was founded in 2018 based on groundbreaking research from the Broad Institute of MIT and Harvard. Tscan Therapeutics has since emerged as a leader in the field of TCR therapies and has attracted significant attention and funding.
Tscan Therapeutics has a diverse pipeline of potential TCR therapies targeting various types of cancer. The company's proprietary TCR technology allows for the identification and engineering of TCRs that can recognize unique cancer-specific antigens. These antigens are surface proteins expressed exclusively on cancer cells, making them ideal targets for TCR therapies.
One of Tscan Therapeutics' key strengths lies in its high-throughput TCR screening platform, enabling efficient identification of TCRs that have the potential to be developed into therapeutic candidates. The company's platform combines next-generation sequencing, proteomics, and bioinformatics to rapidly screen and analyze large libraries of TCRs.
Tscan Therapeutics has also developed innovative methods to enhance the potency and persistence of TCR therapies. These include the use of viral vectors to deliver TCRs into T cells, as well as genetic modifications to improve T cell activity and resistance against tumor immune evasion mechanisms.
The company has collaborations with leading academic institutions and pharmaceutical companies to further advance its TCR therapies. Tscan Therapeutics is actively involved in clinical trials to evaluate the safety and efficacy of its TCR therapies in patients with various types of cancer.
In addition to its core focus on TCR therapies, Tscan Therapeutics is also engaged in research and development efforts to expand its technology platform. This includes the development of novel screening tools, gene editing techniques, and additional immunotherapeutic approaches.
Overall, Tscan Therapeutics Inc is a cutting-edge biotechnology company dedicated to developing effective TCR therapies for the treatment of cancer. With its advanced technology platform, strong pipeline, and strategic partnerships, Tscan Therapeutics is well-positioned to make significant contributions to the field of immunotherapy and improve outcomes for cancer patients.
The company is headquartered in Cambridge, Massachusetts, USA, and was founded in 2018 based on groundbreaking research from the Broad Institute of MIT and Harvard. Tscan Therapeutics has since emerged as a leader in the field of TCR therapies and has attracted significant attention and funding.
Tscan Therapeutics has a diverse pipeline of potential TCR therapies targeting various types of cancer. The company's proprietary TCR technology allows for the identification and engineering of TCRs that can recognize unique cancer-specific antigens. These antigens are surface proteins expressed exclusively on cancer cells, making them ideal targets for TCR therapies.
One of Tscan Therapeutics' key strengths lies in its high-throughput TCR screening platform, enabling efficient identification of TCRs that have the potential to be developed into therapeutic candidates. The company's platform combines next-generation sequencing, proteomics, and bioinformatics to rapidly screen and analyze large libraries of TCRs.
Tscan Therapeutics has also developed innovative methods to enhance the potency and persistence of TCR therapies. These include the use of viral vectors to deliver TCRs into T cells, as well as genetic modifications to improve T cell activity and resistance against tumor immune evasion mechanisms.
The company has collaborations with leading academic institutions and pharmaceutical companies to further advance its TCR therapies. Tscan Therapeutics is actively involved in clinical trials to evaluate the safety and efficacy of its TCR therapies in patients with various types of cancer.
In addition to its core focus on TCR therapies, Tscan Therapeutics is also engaged in research and development efforts to expand its technology platform. This includes the development of novel screening tools, gene editing techniques, and additional immunotherapeutic approaches.
Overall, Tscan Therapeutics Inc is a cutting-edge biotechnology company dedicated to developing effective TCR therapies for the treatment of cancer. With its advanced technology platform, strong pipeline, and strategic partnerships, Tscan Therapeutics is well-positioned to make significant contributions to the field of immunotherapy and improve outcomes for cancer patients.
Tscan Therapeutics Inc is a dynamic biotechnology company specializing in the development and commercialization of T cell receptor (TCR) engineered T cell therapies, with a particular emphasis on combatting cancer. The company operates primarily within the biotechnology and healthcare segments, focusing on innovating immunotherapy solutions to treat solid tumors.
Segments
1. Biotechnology Segment:
- The primary focus of Tscan Therapeutics lies within the biotechnology landscape, specifically emphasizing the advancement of TCR engineered T cell therapies. This segment encompasses all activities related to the identification, development, and commercialization of these therapies, driven by innovations in immuno-oncology.
- In this segment, Tscans efforts are directed towards addressing the complexities of solid tumors, which often present unique challenges due to their heterogeneity and the immunosuppressive microenvironment.
2. Healthcare Segment:
- Within the healthcare sector, Tscan aims to provide transformative treatment options that enhance patient outcomes. The therapies developed by Tscan are designed to empower patients’ immune systems with advanced treatment methodologies that directly engage and eradicate cancerous cells.
Products
Tscan Therapeutics has developed an innovative product line that centers around its flagship TCR engineered T cell therapies:
1. TSC-100:
- TSC-100 represents the company’s leading investigational product, designed specifically to target and eliminate cancer cells associated with various solid tumors. This therapy is distinctive because it is a personalized approach, utilizing the patients unique tumor-specific antigens.
- The manufacturing process involves engineering and reprogramming the patients T cells to express TCRs capable of recognizing specific antigens present on tumor cells. By doing so, TSC-100 aims to provide a more precise, effective, and potentially curative treatment option for patients with challenging cancer types.
The platform used to develop TSC-100 and other therapies involves cutting-edge technologies that identify high-affinity TCRs, facilitating the creation of tailored treatments that align with the immune characteristics of the individual patients cancer.
Services
In addition to its pioneering therapeutic products, Tscan Therapeutics offers a variety of services to enhance the development and application of T cell therapies:
1. Customized TCR Identification:
- Tscans proprietary platform plays a critical role in this service, aimed at discovering and characterizing tumor-specific TCRs that can be leveraged to create personalized T cell therapies. By identifying high-affinity TCRs, Tscan significantly increases the potential effectiveness of the resulting treatments.
2. TCR Engineering:
- The company provides extensive expertise in TCR engineering, essential for modifying T cells to express TCRs that can specifically recognize and target tumor cells. This service underpins the creation of highly targeted T cell therapies, enhancing their efficacy against a diverse range of cancers.
3. Clinical Trial Support:
- Tscan Therapeutics is involved in supporting clinical trials by offering services that include protocol design, developing patient screening methodologies, and monitoring the immune responses during therapeutic interventions. This ensures that therapies are rigorously tested in clinical settings, optimizing their development and regulatory approval.
4. Collaborative Research Partnerships:
- Tscan actively seeks partnerships with academic institutions, biopharmaceutical organizations, and research entities to bolster collaborative research and development efforts. These partnerships are crucial for discovering novel TCRs and advancing the field of T cell therapy, ultimately aiming to expedite their application in clinical practice.
In summary, Tscan Therapeutics Inc is at the forefront of biotechnology innovation focused on TCR engineered T cell therapies, dedicated to evolving the landscape of cancer treatment. By offering a comprehensive suite of targeted therapies and specialized services, the company contributes significantly to the field of immuno-oncology, striving to improve the lives of patients facing solid tumors.
Segments
1. Biotechnology Segment:
- The primary focus of Tscan Therapeutics lies within the biotechnology landscape, specifically emphasizing the advancement of TCR engineered T cell therapies. This segment encompasses all activities related to the identification, development, and commercialization of these therapies, driven by innovations in immuno-oncology.
- In this segment, Tscans efforts are directed towards addressing the complexities of solid tumors, which often present unique challenges due to their heterogeneity and the immunosuppressive microenvironment.
2. Healthcare Segment:
- Within the healthcare sector, Tscan aims to provide transformative treatment options that enhance patient outcomes. The therapies developed by Tscan are designed to empower patients’ immune systems with advanced treatment methodologies that directly engage and eradicate cancerous cells.
Products
Tscan Therapeutics has developed an innovative product line that centers around its flagship TCR engineered T cell therapies:
1. TSC-100:
- TSC-100 represents the company’s leading investigational product, designed specifically to target and eliminate cancer cells associated with various solid tumors. This therapy is distinctive because it is a personalized approach, utilizing the patients unique tumor-specific antigens.
- The manufacturing process involves engineering and reprogramming the patients T cells to express TCRs capable of recognizing specific antigens present on tumor cells. By doing so, TSC-100 aims to provide a more precise, effective, and potentially curative treatment option for patients with challenging cancer types.
The platform used to develop TSC-100 and other therapies involves cutting-edge technologies that identify high-affinity TCRs, facilitating the creation of tailored treatments that align with the immune characteristics of the individual patients cancer.
Services
In addition to its pioneering therapeutic products, Tscan Therapeutics offers a variety of services to enhance the development and application of T cell therapies:
1. Customized TCR Identification:
- Tscans proprietary platform plays a critical role in this service, aimed at discovering and characterizing tumor-specific TCRs that can be leveraged to create personalized T cell therapies. By identifying high-affinity TCRs, Tscan significantly increases the potential effectiveness of the resulting treatments.
2. TCR Engineering:
- The company provides extensive expertise in TCR engineering, essential for modifying T cells to express TCRs that can specifically recognize and target tumor cells. This service underpins the creation of highly targeted T cell therapies, enhancing their efficacy against a diverse range of cancers.
3. Clinical Trial Support:
- Tscan Therapeutics is involved in supporting clinical trials by offering services that include protocol design, developing patient screening methodologies, and monitoring the immune responses during therapeutic interventions. This ensures that therapies are rigorously tested in clinical settings, optimizing their development and regulatory approval.
4. Collaborative Research Partnerships:
- Tscan actively seeks partnerships with academic institutions, biopharmaceutical organizations, and research entities to bolster collaborative research and development efforts. These partnerships are crucial for discovering novel TCRs and advancing the field of T cell therapy, ultimately aiming to expedite their application in clinical practice.
In summary, Tscan Therapeutics Inc is at the forefront of biotechnology innovation focused on TCR engineered T cell therapies, dedicated to evolving the landscape of cancer treatment. By offering a comprehensive suite of targeted therapies and specialized services, the company contributes significantly to the field of immuno-oncology, striving to improve the lives of patients facing solid tumors.